ClinicalTrials.gg
RecruitingNCT07011745Updated Nov 3, 2026

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

A Phase 3 interventional study of Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule in Alzheimer's Disease, sponsored by Bristol-Myers Squibb. Recruiting at 143 sites in 14 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 3, 2026Site recruiting status changed8 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.

Planned enrollment
6th of 10
426 · median 463
Started
2025
with 4 others
Phase 3
10 of 10
10 open now
Registered
9th of 10
by date
Lead sponsor
6 of 10
Bristol-Myers Squibb

Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 6th largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, and was the 9th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing xanomeline in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Alzheimer's Disease (AD)
  • Agitation
  • ADAGIO
  • KarXT
  • KarX-EC
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology:

i) Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), Aβ42/40 ratio in CSF, pTau181/Aβ42 ratio in CSF or pTau217/Aβ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay.

ii) If no historical evidence available:

A. A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval.

B. If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:

  • Amyloid PET.
  • Aβ42/40 ratio or pTau181/Aβ42 ratio in CSF using an HA-authorized diagnostic assay.

    • (MMSE) score of ≤ 24 at Screening (Visit 1).
    • Have an identified caregiver who has sufficient contact (approximately 8 hours over a week) and is willing to:

      i) Attend all visits and report on participant's status.

ii) Oversee participant compliance with medication and study procedures.

iii) Participate in the study assessments and provide to participate in the study.

  • History of agitation that meets the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders with onset at least two weeks prior to Screening (Visit 1).
  • AD participants are required to have NPI/NPI-NH Agitation/Aggression score ≥ 4 at Screening (Visit 1) and Baseline (Visit 2).
  • Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score ≥ 30 at Screening (Visit 1) and Visit 2.

Exclusion criteria

Exclusion Criteria

- Medical Conditions.

i) Agitation symptoms that are primarily attributable to a condition other than the AD causing the dementia.

ii) History of bipolar disorder, schizophrenia, or schizoaffective disorder.

iii) History of (or at high risk for) urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.

iv) Risk of suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSR.

- Prior/Concomitant Therapy.

i) Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (eg, lamotrigine, divalproex), mood stabilizers (eg, lithium), tricyclic antidepressants (eg, imipramine, desipramine), or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam).

A. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening (Visit 1) may be permitted.

B. Trazodone may be used as a hypnotic or for agitation if started at least 8 weeks prior to Screening (Visit 1).

Note: Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening (Visit 1).

- Other protocol-defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
426 participants (estimated)

Study arms

  • Experimental
    KarXT + KarX-EC

    Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugXanomeline/Trospium Chloride Capsule

    Drug pages: Xanomeline · Trospium chloride

    Specified dose on specified days

    Also known as: KarXT, BMS-986510

  • Specified dose on specified days

    Also known as: KarX-EC, BMS-986519

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) total score at Week 14

    Time frame: At Week 14

Secondary outcomes

  1. Change from baseline on the Clinical Global Impressions-Severity (CGI-S) at Week 14

    Time frame: At Week 14

  2. Change from baseline on CMAI-IPA Domains at Week 14

    Time frame: At Week 14

  3. Change from baseline on CMAI Total Score at Week 14

    Time frame: At Week 14

  4. Number of participants with Occurrence of Response at Week 14

    As determined by CMAI-IPA changes of at least 30%, 40%, and 50% from baseline

    Time frame: At Week 14

  5. Change from baseline on the Neuropsychiatric Inventory/Neuropsychiatric Inventory -Nursing Home (NPI/NPI-NH) Total Score at Week 14

    Time frame: At Week 14

  6. Number of participants with Adverse Events (AEs)

    Time frame: Up to Week 18

  7. Number of participants with Treatment Emergent AEs (TEAEs)

    Time frame: Up to Week 18

  8. Number of participants with Serious AEs (SAEs)

    Time frame: Up to Week 18

  9. Number of participants with AEs leading to study drug withdrawal

    Time frame: Up to Week 18

  10. Number of deaths

    Time frame: Up to Week 18

  11. Number of participants with AEs of Special Interest (AESIs)

    Time frame: Up to Week 18

  12. Barnes Akathisia Rating Scale (BARS)

    Time frame: Up to Week 14

  13. Abnormal Involuntary Movement Scale (AIMS)

    Time frame: Up to Week 14

  14. Body weight

    Time frame: Up to Week 14

  15. Body Mass Index (BMI)

    Time frame: Up to Week 14

  16. Number of participants with vital sign abnormalities

    Time frame: Up to Week 18

  17. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Week 14

  18. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Week 14

  19. Number of participants with suicidal ideation as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Week 18

  20. Severity of benign prostatic hyperplasia in male participants as assessed by International Prostate Symptom Score (IPSS)

    Time frame: Up to Week 18

07

Study locations

99 of 143 sites recruiting
  • Chandler Clinical Trials, LLC
    Chandler, Arizona 85224, United States
    Recruiting
    • Ari Magill, Site 2609 · Contact480-382-7909
  • Local Institution - 2631
    Chandler, Arizona 85226-3732, United States
    Not yet recruiting
    • Site 2631 · Contact
  • TrialSphere Corp
    Chandler, Arizona 85286, United States
    Recruiting
    • Hemant Pandey, Site 2646 · Contact520-339-6769
  • National Institute of Clinical Research
    Garden Grove, California 92844, United States
    Recruiting
    • Michael Dao, Site 2625 · Contact
  • Local Institution - 2607
    Long Beach, California 90805, United States
    Not yet recruiting
    • Site 2607 · Contact
  • Accellacare
    Long Beach, California 90807, United States
    Recruiting
    • Elizabeth Zarate Rowell, Site 2642 · Contact
  • Local Institution - 2627
    Napa, California 94558, United States
    Not yet recruiting
    • Site 2627 · Contact
  • ATP Clinical Research
    Orange, California 92866, United States
    Recruiting
    • Gustavo Alva, Site 2649 · Contact949-354-5353
  • Local Institution - 2613
    Pasadena, California 91105, United States
    Not yet recruiting
    • Site 2613 · Contact
  • Local Institution - 2614
    San Diego, California 92108, United States
    Not yet recruiting
    • Site 2614 · Contact
  • Local Institution - 2620
    West Hills, California 91307, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2601
    Basalt, Colorado 81621, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 2632
    Norwalk, Connecticut 06851, United States
    Not yet recruiting
    • Site 2632 · Contact
  • Visionary Investigators Network
    Aventura, Florida 33180, United States
    Recruiting
    • Jonathan Cross, Site 2648 · Contact305-933-5993
  • Envision Trials LLC
    Bonita Springs, Florida 34134-4154, United States
    Recruiting
    • Daniel Mandri, Site 2602 · Contact305-819-2909
  • Key Clinical Research
    Bradenton, Florida 34207, United States
    Recruiting
    • Nicholas Weber, Site 2624 · Contact+61736460818
  • Local Institution - 2636
    Doral, Florida 33122, United States
    Not yet recruiting
    • Site 2636 · Contact
  • Local Institution - 2606
    Homestead, Florida 33032, United States
    Not yet recruiting
    • Site 2606 · Contact
  • Miami Jewish health
    Miami, Florida 33137, United States
    Recruiting
    • Marc Agronin, Site 2633 · Contact3057518626x2403
  • Local Institution - 2637
    Miami, Florida 33165, United States
    Not yet recruiting
    • Site 2637 · Contact
  • Local Institution - 2634
    Orlando, Florida 32806, United States
    Not yet recruiting
    • Site 2634 · Contact
  • IPTB Clinical Research
    Tampa, Florida 33629, United States
    Recruiting
    • Jamie Fernandez, Site 2621 · Contact813-251-1800
  • Agile Clinical Research Trials, LLC
    Atlanta, Georgia 30328, United States
    Recruiting
    • Vasundhara Cheekati, Site 2611 · Contact404-382-8660
  • Local Institution - 2615
    Worcester, Massachusetts 01608, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2618
    Ann Arbor, Michigan 48105, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2630
    Saint Paul, Minnesota 55130, United States
    Not yet recruiting
    • Site 2630 · Contact
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39402, United States
    Recruiting
    • Ronald Schwartz, Site 2629 · Contact601-606-0911
  • Local Institution - 2603
    Ozark, Missouri 65721, United States
    Completed

    Not enrolling at this site — choose another above.

  • Las Vegas Clinical Trials
    Las Vegas, Nevada 89030, United States
    Recruiting
    • Alton Walters, Site 2628 · Contact702-637-3223
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
    Recruiting
    • Ashok Patel, Site 2650 · Contact732-244-2299
  • Local Institution - 2647
    Brooklyn, New York 11229, United States
    Not yet recruiting
    • Site 2647 · Contact
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
    Recruiting
    • Romana Kulikova, Site 2619 · Contact718-619-4403
  • Walnut Clinical Research
    Valley Stream, New York 11580, United States
    Recruiting
    • Osher Rechester, Site 2644 · Contact718-407-0225
  • West Clinical Research
    Morehead City, North Carolina 28557, United States
    Recruiting
    • Patrick Morgante, Site 2608 · Contact252-515-0050
  • Velocity Clinical Research - Blue Ash
    Blue Ash, Ohio 45242, United States
    Recruiting
    • Babu Gupta, Site 2617 · Contact513-769-2767
  • Epic Medical Research, LLC - Carrolton
    Carrollton, Texas 75006, United States
    Recruiting
    • Andrea Brown, Site 2616 · Contact972-782-2405
  • Horizon Clinical Research Center - Houston
    Cypress, Texas 77429, United States
    Recruiting
    • Harpaul Gill, Site 2605 · Contact949-491-0710
  • Epic Medical Research, LLC - Mesquite
    Mesquite, Texas 75150, United States
    Recruiting
    • Laquita Shepherd, Site 2622 · Contact972-777-6956
  • UT Health - San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Antonio Teixeira, Site 2623 · Contact210-567-8229
  • Local Institution - 2612
    Bountiful, Utah 84010, United States
    Completed

    Not enrolling at this site — choose another above.

  • EvergreenHealth Medical Center
    Kirkland, Washington 98034, United States
    Recruiting
    • Pinky Agarwal, Site 2638 · Contact425-899-3123
  • Local Institution - 2610
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
    • Site 2610 · Contact
  • Centro Neurobiológico y de Estrés Traumático - CENydET S.R.L.
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1058, Argentina
    Recruiting
    • Enrique Kuper, Site 2005 · Contact541143000000
  • Fundacion para el Estudio y Tratamiento de Enfermedades mentales- FETEM
    Buenos Aires, 1133, Argentina
    Recruiting
    • Ricardo Corral, Site 2006 · Contact5491144455572
  • Hospital Italiano de Buenos Aires (HIBA)
    Buenos Aires, 1199, Argentina
    Recruiting
    • José Faccioli, Site 2004 · Contact+5491157934078
  • Instituto Modelo de Neurología, Fundación Lennox
    Córdoba, 5000, Argentina
    Recruiting
    • Georgina Viczena, Site 2000 · Contact+5493515993881
  • Sanatorio Morra S.A.
    Córdoba, 5000, Argentina
    Recruiting
    • Carlos Morra, Site 2002 · Contact5493516858696
  • Instituto Médico DAMIC
    Córdoba, X5003DCE, Argentina
    Recruiting
    • Gerardo Garcia Bonetto, Site 2003 · Contact+5493516508068
  • Resolution Psychopharmacology Research Institute
    Mendoza, 5502, Argentina
    Recruiting
    • Eugenio Velasco, Site 2001 · Contact54-261-9-155861633
  • Biomedica Research Group
    Santiago, Santiago Metropolitan 7500710, Chile
    Recruiting
    • Sergio Gloger, Site 2051 · Contact+56982945977
  • Local Institution - 2050
    Santiago, Santiago Metropolitan 7560356, Chile
    Not yet recruiting
    • Site 2050 · Contact
  • Pontificia Universidad Catolica de Chile
    Santiago, Santiago Metropolitan 8330024, Chile
    Recruiting
    • Rodrigo Santibanez Moreira, Site 2052 · Contact56940920180
  • Clinica Alemana
    Vitacura, Santiago Metropolitan 2511433, Chile
    Recruiting
    • Rafael Aranguiz, Site 2054 · Contact005622910 2853
  • Local Institution - 2055
    Viña del Mar, Valparaiso 2511433, Chile
    Not yet recruiting
    • Site 2055 · Contact
  • Psicomed Estudios Médicos Cía Ltda
    Antofagasta, 1270244, Chile
    Recruiting
    • Luis Alberto Barra Ahumada, Site 2053 · Contact5655240334
  • AGE Centrum
    Olomouc, Olomouc Region 779 00, Czechia
    Recruiting
    • Dagmar Malotova, Site 2107 · Contact00420723060809
  • Neuropsychiatrie
    Prague, Praha 6 160 00, Czechia
    Recruiting
    • Jakub Hort, Site 2100 · Contact+420224434700
  • Institut neuropsychiatricke pece (INEP), Praha
    Prague, Praha 8 18600, Czechia
    Recruiting
    • Alexander Nawka, Site 2106 · Contact+420605809745
  • Neuro Health Centrum s.r.o.
    Brno, South Moravian 628 00, Czechia
    Recruiting
    • Katerina Sheardova, Site 2103 · Contact+420603198029
  • NEUROHK
    Choceň, 565 01, Czechia
    Recruiting
    • Martin Valis, Site 2101 · Contact+420495835233
  • A-SHINE s.r.o.
    Pilsen, 301 00, Czechia
    Recruiting
    • Lubos Janu, Site 2104 · Contact420777242101
  • Local Institution - 2102
    Prague, 100 000, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 2105
    Prague, 100 00, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Vestra Clinics s.r.o.
    Rychnov nad Kněžnou, 516 01, Czechia
    Recruiting
    • Ladislav Pazdera, Site 2108 · Contact420604236033
  • Centre Hospitalier Universitaire Toulouse - Cité de la Santé
    Toulouse, Haute-Garonne 31000, France
    Recruiting
    • Maria Eugenia Soto-Martin, Site 2150 · Contact
  • Hôpital des Charpennes - Hospices Civils de Lyon (HCL)
    Villeurbanne, Rhône 69100, France
    Recruiting
    • Antoine Garnier-Crussard, Site 2151 · Contact
  • Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro
    Lille, 59037, France
    Recruiting
    • Lionel Trogneux, Site 2153 · Contact0320446021
  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren
    Limoges, 87042, France
    Recruiting
    • Achille Tchalla, Site 2156 · Contact+555058262
  • Hopital Gui Chauliac - Chu Montpellier
    Montpellier, 34295, France
    Recruiting
    • Karim Bennys, Site 2157 · Contact33467336029
  • Centres Memoire de Ressources et de Recherche (CMRR) - Hopital Lariboisiere-Fernand-Widal Location
    Paris, 75010, France
    Recruiting
    • Emmanuel COGNAT, Site 2152 · Contact
  • Les Hôpitaux Universitaires de Strasbourg - Hôpital de la Robertsau
    Strasbourg, 67091, France
    Recruiting
    • Alix RAVIER, Site 2155 · Contact+33388115844
  • Local Institution - 2201
    Düsseldorf, 40221, Germany
    Not yet recruiting
    • Site 2201 · Contact
  • Local Institution - 2205
    Halle, 06120, Germany
    Not yet recruiting
    • Site 2205 · Contact
  • Local Institution - 2206
    Westerstede, 26655, Germany
    Not yet recruiting
    • Site 2206 · Contact
  • Local Institution - 2257
    Kalocsa, Bács-Kiskun county 6300, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 2250
    Győr, Győr-Moson-Sopron 0, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdú-Bihar 4031, Hungary
    Recruiting
    • Palma Piros, Site 2252 · Contact36206207623
  • Local Institution - 2256
    Budapest, 1033, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 2251
    Budapest, 1083, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Semmelweis Egyetem
    Budapest, 1083, Hungary
    Recruiting
    • Tibor Kovacs, Site 2253 · Contact+36 20 825 0367
  • Local Institution - 2255
    Dunaújváros, 2400, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 2254
    Gyöngyös, 3200, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • The Chaim Sheba Medical Center
    Ramat Gan, Central District 5262000, Israel
    Recruiting
    • Ramit Ravona-Springer, Site 2305 · Contact
  • Local Institution - 2302
    Petch Tikva, IL 49100, Israel
    Not yet recruiting
    • Site 2302 · Contact
  • Sanz MC, Laniado Hospital
    Netanya, 4244916, Israel
    Recruiting
    • Vered Hermush, Site 2303 · Contact
  • The Israeli Alzheimer Medical Center
    Ramat Gan, 5265601, Israel
    Recruiting
    • Mark Weiser, Site 2300 · Contact0526666570
  • Bayit Balev Ltd.
    Rishon Le'Tzion, 7590653, Israel
    Recruiting
    • Gisele Sasson, Site 2304 · Contact
  • University of Naples Federico II
    Naples, Campania 80131, Italy
    Recruiting
    • Vincenzo Brescia Morra, Site 2351 · Contact+39081743741
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Viale del Policlinico 155
    Rome, Lazio 00185, Italy
    Recruiting
    • Giuseppe Bruno, Site 2354 · Contact3988888888x88
  • Azienda Ospedaliero-Universitaria Sant'Andrea
    Rome, Lazio 00189, Italy
    Recruiting
    • Franco Giubilei, Site 2352 · Contact390633775630
  • Auxologico IRCCS - Auxologico San Luca
    Milan, Lombardy 20149, Italy
    Recruiting
    • Nicola Ticozzi, Site 2353 · Contact3902619112937
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, PI 56126, Italy
    Recruiting
    • giulio perugi, Site 2350 · Contact+39335435387
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
    Recruiting
    • Salvatore Caratozzolo, Site 2356 · Contact+393930406304
  • Local Institution - 2355
    Isernia, 86077, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fondazione Policlinico Gemelli IRCCS
    Roma, 00168, Italy
    Recruiting
    • Francesco Landi, Site 2357 · Contact+39 0630154859
  • Centrum Medyczne HCP Szpital im. Jana Pawla II
    Poznan, Greater Poland Voivodeship 61-485, Poland
    Recruiting
    • Przemyslaw Osip, Site 2450 · Contact+48604116632
  • Centrum Medyczne NEUROMED
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-163, Poland
    Recruiting
    • Pawel Lisewski, Site 2454 · Contact0048698619497
  • M2M Med
    Chorzów, 41-500, Poland
    Recruiting
    • Anna Starostka-Tatar, Site 2456 · Contact+48518424470
  • Local Institution - 2455
    Katowice, 40-146, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2458
    Krakow, 31-505, Poland
    Not yet recruiting
    • Site 2458 · Contact

Showing the first 100 of 143 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2028, 39 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 39 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Nov 3, 2028
CompletionEst.
Nov 13, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 9 sites removed. 2 sites changed recruiting status (2 now withdrawn)
Show 2 sites
  • Local Institution - 2257 · Kalocsa, HungaryNot yet recruiting→Withdrawn
  • Local Institution - 2256 · Budapest, HungaryNot yet recruiting→Withdrawn
Show 8 added (2 United States, 2 Hungary, 2 Poland, 2 Ukraine)
  • Visionary Investigators Network · Aventura, United States
  • Local Institution - 2254 · Gyöngyös, Hungary
  • Local Institution - 2455 · Katowice, Poland
  • Bio Behavioral Health · Toms River, United States
  • Local Institution - 2255 · Dunaújváros, Hungary
  • NZOZ Wrocławskie Centrum Alzheimerowskie · Wroclaw, Poland
  • Kyiv Clinical Hospital on Railway Transport No. 1 of the branch "Health Center" of Joint Stock Company "Ukrainian railways" · Kyiv, Ukraine
  • Municipal non-commercial enterprise "Ternopil regional clinical psychoneurological hospital of the Ternopil regional board" · Ternopil, Ukraine
Show 9 removed
  • Local Institution - 2648 · Aventura, United States
  • Local Institution - 2008 · Río Cuarto, Argentina
  • Local Institution - 2254 · Gyöngyös, Hungary
  • Centrum In Psyche Spersonalizowanej Psychiatrii I Terapii · Katowice, Poland
  • Local Institution - 2650 · Toms River, United States
  • Local Institution - 2255 · Budapest, Hungary
  • Local Institution - 2457 · Wroclaw, Poland
  • Local Institution - 2565 · Kyiv, Ukraine
  • Local Institution - 2562 · Ternopil, Ukraine
across 2 updates, Oct 8, 2026 – Nov 3, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Local Institution - 2257 · Kalocsa, HungaryContact removed (no phone or email listed)
  • Local Institution - 2256 · Budapest, HungaryContact removed (no phone or email listed)
across 2 updates, Oct 8, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    5 sites added, 5 sites removed. Local Institution - 2256 is now Withdrawn
    Show 5 added (2 Ukraine, 1 United States, 1 Hungary, 1 Poland)
    • Bio Behavioral Health · Toms River, United States
    • Local Institution - 2255 · Dunaújváros, Hungary
    • NZOZ Wrocławskie Centrum Alzheimerowskie · Wroclaw, Poland
    • Kyiv Clinical Hospital on Railway Transport No. 1 of the branch "Health Center" of Joint Stock Company "Ukrainian railways" · Kyiv, Ukraine
    • Municipal non-commercial enterprise "Ternopil regional clinical psychoneurological hospital of the Ternopil regional board" · Ternopil, Ukraine
    Show 5 removed
    • Local Institution - 2650 · Toms River, United States
    • Local Institution - 2255 · Budapest, Hungary
    • Local Institution - 2457 · Wroclaw, Poland
    • Local Institution - 2565 · Kyiv, Ukraine
    • Local Institution - 2562 · Ternopil, Ukraine
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Local Institution - 2256 · Budapest, HungaryContact removed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 8, 2026
    3 sites added, 4 sites removed. Local Institution - 2257 is now Withdrawn
    Show 3 added (1 United States, 1 Hungary, 1 Poland)
    • Visionary Investigators Network · Aventura, United States
    • Local Institution - 2254 · Gyöngyös, Hungary
    • Local Institution - 2455 · Katowice, Poland
    Show 4 removed
    • Local Institution - 2648 · Aventura, United States
    • Local Institution - 2008 · Río Cuarto, Argentina
    • Local Institution - 2254 · Gyöngyös, Hungary
    • Centrum In Psyche Spersonalizowanej Psychiatrii I Terapii · Katowice, Poland
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Local Institution - 2257 · Kalocsa, HungaryContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07011745
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jul 16, 2025
Primary completion
Nov 3, 2028 (estimated)
Completion
Nov 13, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion